14 min listen
Tumor Staging of Endocervical Carcinoma with Esther Oliva
FromIJGC Podcast
ratings:
Length:
35 minutes
Released:
May 17, 2021
Format:
Podcast episode
Description
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Esther Olvia to discuss tumor staging of endocervical carcinoma. Dr. Oliva is a Pathologist at Massachusetts General Hospital and Professor at Harvard Medical School and have been the recent past president of the International Society of Gynecologic Pathologists. She was born in Barcelona and trained under three giants of pathology, Dr. Robert E. Scully, Dr. Robert H. Young, and Dr. Jaime Prat.
Highlights
- Create awareness of difficulties encountered by pathologists when reporting findings on different cervical specimens for endocervical adenocarcinoma
- Highlight efforts to reach consensus among pathologists to standardize reporting for cervical specimens with adenocarcinoma
- Highlight the importance of synchronization between FIGO, TNM, and AJCC
- Clarify important issues in staging of endocervical adenocarcinoma including but not limited to measuring grossly visible tumor, exophytic tumors, and circumferential tumors, approach when dealing with multiple specimens or multiple tumors, and reporting tumor at margins
- Highlight areas that need more studies in order to provide useful recommendations, including ovarian involvement by endocervical adenocarcinoma, quantification of lymphovascular invasion, or evaluation of isolated tumor Cells among others.
Highlights
- Create awareness of difficulties encountered by pathologists when reporting findings on different cervical specimens for endocervical adenocarcinoma
- Highlight efforts to reach consensus among pathologists to standardize reporting for cervical specimens with adenocarcinoma
- Highlight the importance of synchronization between FIGO, TNM, and AJCC
- Clarify important issues in staging of endocervical adenocarcinoma including but not limited to measuring grossly visible tumor, exophytic tumors, and circumferential tumors, approach when dealing with multiple specimens or multiple tumors, and reporting tumor at margins
- Highlight areas that need more studies in order to provide useful recommendations, including ovarian involvement by endocervical adenocarcinoma, quantification of lymphovascular invasion, or evaluation of isolated tumor Cells among others.
Released:
May 17, 2021
Format:
Podcast episode
Titles in the series (100)
The Use of Parp Inhibitors in Advanced Ovarian Cancer with Robert Coleman: In this episode of the IJGC podcast, Editor-in-Ch… by IJGC Podcast